Avui, dijous 7 de maig, el Dipòsit Digital no estarà operatiu per tasques d'actualització. Disculpeu les molèsties.
Hoy, jueves 7 de mayo, el Dipòsit Digital no estará operativo debido a tareas de actualización. Disculpen las molestias.
Today, Thursday, May 7th, the Digital Repository will be unavailable due to a system update.

Fitxers

649059.pdf (211.67 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2014-06-20

Llicència de publicació

cc-by-nc (c) Ascher-Svanum, H. et al., 2014
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/65757

Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection 

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

http://dx.doi.org/10.2147/NDT.S61409

Resum

BACKGROUND: Little is known about the long-term changes in the functioning of schizophrenia patients receiving maintenance therapy with olanzapine long-acting injection (LAI), and whether observed changes differ from those seen with oral olanzapine. METHODS: This study describes changes in the levels of functioning among outpatients with schizophrenia treated with olanzapine-LAI compared with oral olanzapine over 2 years. This was a secondary analysis of data from a multicenter, randomized, open-label, 2-year study comparing the long-term treatment effectiveness of monthly olanzapine-LAI (405 mg/4 weeks; n=264) with daily oral olanzapine (10 mg/day; n=260). Levels of functioning were assessed with the Heinrichs-Carpenter Quality of Life Scale. Functional status was also classified as 'good', 'moderate', or 'poor', using a previous data-driven approach. Changes in functional levels were assessed with McNemar's test and comparisons between olanzapine-LAI and oral olanzapine employed the Student's t-test. RESULTS: Over the 2-year study, the patients treated with olanzapine-LAI improved their level of functioning (per Quality of Life total score) from 64.0-70.8 (P<0.001). Patients on oral olanzapine also increased their level of functioning from 62.1-70.1 (P<0.001). At baseline, 19.2% of the olanzapine-LAI-treated patients had a 'good' level of functioning, which increased to 27.5% (P<0.05). The figures for oral olanzapine were 14.2% and 24.5%, respectively (P<0.001). Results did not significantly differ between olanzapine-LAI and oral olanzapine. CONCLUSION: In this 2-year, open-label, randomized study of olanzapine-LAI, outpatients with schizophrenia maintained or improved their favorable baseline level of functioning over time. Results did not significantly differ between olanzapine-LAI and oral olanzapine.

Matèries

Antipsicòtics, Esquizofrènia, Qualitat de vida

Matèries (anglès)

Antipsychotic drugs, Schizophrenia, Quality of life

Citació

Col·leccions

Articles publicats en revistes (Psicologia Clínica i Psicobiologia)

Citació

ASCHER-SVANUM, Haya, et al. Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection . Neuropsychiatric Disease And Treatment. 2014. Vol. 10, núm. 1125-1131. ISSN 1176-6328. [consulta: 8 de maig de 2026]. Disponible a: https://hdl.handle.net/2445/65757

Exportar metadades

JSON - METS

Compartir registre